Gastroenterology and Endoscopy Unit, University Hospital of Parma, University of Parma, 43125, Parma, Italy.
Department of Clinical Research, University of Southern Denmark, 5230, Odense, Denmark; Department of Surgery, Odense University Hospital, 5000, Odense, Denmark.
Dig Liver Dis. 2024 Apr;56(4):601-606. doi: 10.1016/j.dld.2023.07.028. Epub 2023 Aug 8.
BACKGROUND & AIMS: The role of small-bowel (SB) cancer surveillance by capsule endoscopy (CE) in Lynch syndrome (LS) patients has been investigated in recent years, with contradicting results. This meta-analysis evaluates the diagnostic yield (DY) of CE as a screening tool in asymptomatic LS patients.
A systematic literature search was performed for all studies reporting the results of SB cancer screening in patients with LS. The primary outcome was the evaluation of the DY of CE in this setting for consecutive screening rounds.
Five studies comprising 428 patients and CE 677 procedures were included for data extraction and statistical analysis. The estimated pooled DY for CE-identified pathological findings was 8% in the first screening round and 6% in the second. Limiting the analysis to histologically-confirmed pathological findings, the pooled DY of second-round screening dropped to 0%. The included studies showed a significantly different prevalence of pathogenic variants in mismatch repair (path_MMR) genes, which underlie different cumulative incidences of extracolonic cancers.
SB surveillance by CE with a 2-year interval in asymptomatic LS individuals does not appear to be an effective screening strategy. Confirmatory prospective studies in this context are needed, considering the different cumulative incidence of SB tumors according to underlying path_MMR defects.
近年来,胶囊内镜(CE)在林奇综合征(LS)患者中小肠(SB)癌监测的作用已经过研究,但其结果存在争议。本荟萃分析评估了 CE 作为无症状 LS 患者筛查工具的诊断收益(DY)。
对所有报道 LS 患者 SB 癌筛查结果的研究进行了系统的文献检索。主要结局是评估 CE 在连续筛查轮次中的 DY。
纳入了 5 项研究,共 428 例患者和 677 例 CE 检查,用于数据提取和统计分析。CE 发现的病理结果的估计汇总 DY 在第一轮筛查中为 8%,第二轮为 6%。将分析仅限于组织学证实的病理结果,第二轮筛查的汇总 DY 降至 0%。纳入的研究显示,错配修复(path_MMR)基因中的致病性变异的患病率存在显著差异,这是导致不同结外癌症累积发生率的原因。
在无症状 LS 个体中,间隔 2 年进行 SB 监测的 CE 似乎不是一种有效的筛查策略。考虑到潜在的 path_MMR 缺陷导致的 SB 肿瘤累积发生率不同,在这种情况下需要进行确认性的前瞻性研究。